Trial Profile
Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers in an Open Label, Single-dose and Parallel Study Design
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jul 2014
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary) ; Linagliptin (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 15 Jul 2014 New trial record